Schizophrenia | Access and Reimbursement | Depot Antipsychotic Use | US | 2017
Despite the availability of multiple oral atypical antipsychotics in the United States, long-acting depot formulations of atypical antipsychotics offer a compelling advantage because of their less frequent dosing schedules and the associated potential for increased patient compliance, reduced rate of hospitalizations, and overall lower cost of care. Largely due to the availability of these less expensive oral therapies, depot atypical antipsychotics are typically reserved for late lines of therapy and often are subject to reimbursement restrictions that hinder their access. Given that generic versions of some depot agents are expected to launch in the United States in the coming years (e.g., Janssen’s Risperdal Consta), branded depot agents may become even more difficult to access. Emerging depot antipsychotics will need to offer unique benefits to gain a foothold in this market.
Questions Answered:
- What is the coverage status of depot atypical antipsychotic agents on Medicaid and commercial healthcare plans, including the most recently approved drugs (e.g., Alkermes’s Aristada, Janssen’s Invega Trinza)?
- How do reimbursement restrictions impact psychiatrists’ prescribing of depot atypical antipsychotics to their schizophrenia patients, and what distribution channels are used to access these therapies?
- How do payers anticipate that generic versions of depot atypical antipsychotics will impact access to the branded originator therapies? How do psychiatrists expect to prescribe these generics?
- How do psychiatrists anticipate prescribing emerging depot antipsychotic agents (e.g., Indivior’s RBP-7000), and how do payers expect to cover these therapies at various price points on commercial health plans?
Product Description:
Access & Reimbursement: Provides in-depth insight regarding the impact of payer policy on physician prescribing behavior so you can build your market access strategy and optimize your brand positioning.
